Article Sidebar
Main Article Content
Abstract
Background: Tuberculosis is the most common cause of death in HIV patients. Indoleamine 2,3-dioxygenase 1 (IDO1) is an enzyme that plays a crucial role in the immune response to TB and HIV infection. Increased plasma IDO1 activity in TB patients can be a promising marker for the diagnosis of TB, especially in HIV patients. This study aimed to evaluate the differences in the activity of indoleamine 2,3-dioxygenase 1 plasma of HIV-positive pulmonary TB with HIV-negative pulmonary TB patients.
Methods: This study is an analytic observational study. Plasma IDO1 activity was assessed by calculating the kynurenine/tryptophan ratio (K/T ratio). This indicator was assessed on 28 lung TB patients divided into two groups, HIV-positive pulmonary TB and HIV-negative pulmonary TB group.
Results: Twenty-eight subjects were included in this study with a mean age of 42,96 (16,17) years, with more males than females. This study's mean K/T ratio was 0.18 (0.16), with HIV-positive pulmonary TB is higher than HIV-negative pulmonary TB (0.24 vs 0.12, p = 0.027).
Conclusion: There is a significant difference in the Indoleamine 2,3-dioxygenase 1 (IDO1) plasma in HIV-positive pulmonary TB and HIV-negative pulmonary TB groups. Thus the IDO1 plasma can be used as a new biomarker in diagnosed TB in HIV patients.
Keywords
Article Details
As our aim is to disseminate original research article, hence the publishing right is a necessary one. The publishing right is needed in order to reach the agreement between the author and publisher. As the journal is fully open access, the authors will sign an exclusive license agreement.
The authors have the right to:
- Share their article in the same ways permitted to third parties under the relevant user license.
- Retain copyright, patent, trademark and other intellectual property rights including research data.
- Proper attribution and credit for the published work.
For the open access article, the publisher is granted to the following right.
- The non-exclusive right to publish the article and grant right to others.
- For the published article, the publisher applied for the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
